ZYBERNO
Stock Report
Updated Sep 1, 2026

GLUCOTRACK, INC. (GCTK)

Healthcare • NASDAQ

$3.68

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
0.0/100
POOR BUSINESS
GLUCOTRACK, INC. (GCTK) scores 0/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-2,135.5%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-3,113.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

GLUCOTRACK, INC. (GCTK) stock report — Zyberno Score 0/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, GCTK generated -$15.34M in Owner Earnings. Capital was deployed as follows: $96.00K invested in capital expenditures. Reinvestment rate: -0.5%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:3.68
Market Cap:$18.43M

Valuation Multiples (2)

Enterprise Metrics (1)

Enterprise Value:$17.48M

Price Action & Momentum (1)

% of 52-Week High:2.5%
B. Profitability Assessment

Return Metrics (5)

ROA:-290.2%
Reinvestment Rate:-0.5%
Fundamental Growth Rate (g):14.6%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:$6.99K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-89.9%
Latest Earnings Filed:2026-08-14
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.46x
Quick Ratio:0.46x
Cash Ratio:0.38x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-3,218.00x
Times Interest Earned:-3,218.00

Capital Structure (4)

Working Capital:-1,607,000.00
Cash And Cash Equivalents:1,124,000.00
Long Term Debt:$5.00K
Net Debt:-$958.00K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$15.40M

Bottom Line Performance (3)

-$15.95M
Income Before Tax:$0.00
Ebitda Ttm:-15,357,000.00

Operating Expenses (5)

Operating Expenses:15,399,000.00
R And D Expense:8,940,000.00
Sga Expense:6,769,000.00
Income Tax Expense:$0.00
Interest Expense:5,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$1.50M
Current Assets:$1.38M
Ppe Net:95,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:3,236,000.00
Current Liabilities:2,988,000.00
Long Term Debt:$5.00K
Short Term Debt:$161.00K

Equity & Capital (3)

Equity:-$1.74M
Retained Earnings:-$159.99M
Common Stock:250,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,116,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:61,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$16.35M-$16.45M

Investment Activities (2)

Investing Cash Flow:-$20.00K
Capital Expenditures Ttm:96,000.00

Financing Activities (3)

Financing Cash Flow:$591.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):25.68
Eps diluted TTM: $25.68
Linear Growth: -34.4%
📊 Click to view full GCTK EPS analysis & methodology →
Earnings Per Share Ttm:-$3.18

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$3.04

Book Value & Capital (2)

Book Value Per Share:-$0.35
Cash Per Share:0.22

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:10.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$15.34M

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.5%
Fundamental Growth Rate (g):14.6%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):31.1%
C. Company Profile & Context

Corporate Information (6)

Symbol:GCTK
Company Name:GLUCOTRACK, INC.
Sector:Healthcare
Industry:Medical Devices
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:5.01M
Shares Outstanding Basic:5.01M
Shares Outstanding Diluted:5.01M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 20:25:31 UTC
Data Timestamp:2026-08-22T10:13:04.292175
Scroll to Top